We studied absorption, efficacy, and tolerability in Parkinson's disease (PD) of a new preparation of apomorphine included in a microemulsion and administered by transdermal route (Apo-MTD). Twenty-one PD patients were treated with levodopa plus oral dopamine-agonists (T0), with levodopa alone (T1), finally with levodopa plus Apo-MTD (T2). Apo-MTD provided therapeutic plasma levels for many hours, improved Unified Parkinson's Disease Rating Scale III scores, and reduced total duration of off periods compared to T0 and T1. We concluded that Apo-MTD is absorbed and demonstrates clinical efficacy and long action. Therefore, it seems a promising add-on treatment for uncontrolled prolonged off phases in PD patients, but chronic tolerability needs further study.
|Titolo:||Transdermal apomorphine permeation from microemulsions : a new treatment in Parkinson's disease|
|Parole Chiave:||Apomorphine; Dopamine agonists; Parkinson's disease; Pharmacokinetics; Transdermal|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||ago-2004|
|Digital Object Identifier (DOI):||10.1002/mds.20054|
|Appare nelle tipologie:||01 - Articolo su periodico|